Skip to main content
OpenTrials
Completed

NCT Number: NCT04841993

Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation

The purposes of the study are 1) to know the concentrations of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids in blood, urine, oral fluid and sweat after the experimental administration of a standardized cannabis preparation orally (decoction and oil) and vaporized 2) to evaluate the pharmacological acute effects and tolerability

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cannabis Use Healthy Subjects

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Germans Trias i Pujol Hospital

Badalona, Barcelona, 08916, Spain

About this study

Medical cannabis" encompasses the use of cannabis and cannabinoids for therapeutic purposes. Includes drugs approved by regulatory agencies and pharmaceutical products. Recently, many countries have authorized the use of cannabis flower cups with a standardized amount of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and their acidic precursors (Δ-9-tetrahydrocannabinolic acid A [THCA] and cannabidiol acid [ CBDA]) for the treatment of different diseases. In Italy since January 2017 there has been for sale a standardized cannabis preparation produced by the Military Pharmaceutical Institute of Florence. This medicinal variety of cannabis sativa, known as FM2 has a variable THC and CBD percentage of between 5-8% and 7-12% respectively. To date, there are no studies on the pharmacokinetics of THC, CBD and other minor cannabinoids in conventional and unconventional biological matrices after oral administration of cannabis tea, cannabis oil and vaporized with the same medicinal preparation (FM2). The main objective is to know the concentrations of THC, CBD and metabolites, and other cannabinoids in blood, urine, oral fluid and sweat after the experimental administration of a standardized cannabis preparation orally (two formulations: cannabis tea and cannabis oil) and vaporized. In addition, the acute pharmacological effects and tolerability will be evaluated. Healthy recreational cannabis users with experience in oral use of cannabis will participate

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Understanding and accepting the study procedures and signing the informed consent.
  • Male and females healthy volunteers (18-45 years old.
  • History and physical examination showing no organic or psychiatric disorders.
  • The EKG and the blood chemistry and hematology at inclusion must be within the limits of normality. Minor or specific variations of the limits of normality are admitted if, in the opinion of the Principal Investigator, taking into account the state of science, they do not have clinical significance, do not pose a risk to the subjects and do not interfere with the evaluation of the product. These variations and their non-relevance will be specifically justified in writing.
  • Body weight between 50-90 kilograms. Lower or higher weights are allowed, in the opinion of the Principal Investigator or the collaborators designated by him and that do not pose a risk to the subjects and do not interfere with the objectives of the study.
  • BMI between 19-27 kg / m². Lower or higher BMIs are admitted, which in the opinion of the Principal Investigator or the collaborators designated by him that do not pose a risk to the subjects and do not interfere with the objectives of the study.
  • Women with a menstrual cycle that lasts between 26-32 days and is regular.
  • Subjects with social or recreational consumption of cannabis in the last 12 months and consumption of oral cannabis at least once in their life (eg cake, cookies, oils, infusion…).

Exclusion criteria

  • Not meeting the inclusion criteria.
  • History or clinical evidence of gastrointestinal, liver, kidney or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.
  • Current or previous history of Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) substance use disorder (except nicotine and mild cannabis use disorder or DSM-IV for substance use disorder or abuse).
  • Having donated blood in the previous 8 weeks, or having participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks, except for having previously participated in this same study, in which a 3-week washout period is sufficient.
  • Having suffered any organic disease or major surgery in the three months prior to the start of the study.
  • Subjects who are intolerant or have had serious adverse reactions to cannabis.
  • Having taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies or dietary supplements that, in the opinion of the Principal Investigator or the collaborators designated by him, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to the study sessions will not be grounds for exclusion if it is assumed that it has been completely eliminated on the day of the experimental session.
  • Smokers of more than 15 cigarettes a day.
  • Subjects who are uncapable of understanding the nature of the trial and the procedures they are required to follow.
  • Subjects with positive serology for hepatitis B, C or HIV.
  • Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner).
  • Women with amenorrhea or severe premenstrual syndrome.

Treatment and study plan

Cannabis decoction

Drug

A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.

Other names: Cannabis tea

Cannabis oil

Drug

A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.

Vaporized cannabis

Drug

100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD

Other names: Inhaled cannabis

Primary outcomes

  1. Maximum serum concentration (Cmax) of THC

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Calculation of maximum concentration (ng/mL) in samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  2. Maximum serum concentration (Cmax) of THCA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Calculation of maximum concentration (ng/mL) in samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  3. Maximum serum concentration (Cmax) of CBD

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Calculation of maximum concentration (ng/mL) in samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  4. Maximum serum concentration (Cmax) of CBDA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Calculation of maximum concentration (ng/mL) in samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  5. Time to reach maximum serum concentration (Tmax) of THC

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations.

  6. Time to reach maximum serum concentration (Tmax) of THCA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations.

  7. Time to reach maximum serum concentration (Tmax) of THC metabolites

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations.

  8. Time to reach maximum serum concentration (Tmax) of CBD

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations.

  9. Time to reach maximum serum concentration (Tmax) of CBDA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration.

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations.

  10. Area under the concentration-time curve (AUC 0-24 h) of THC in serum concentrations

    Time frame: From baseline to 24 hours after administration ( decoction, oil or vaporized cannabis )

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  11. Area under the concentration-time curve (AUC 0-24 h) of THCA in serum concentrations

    Time frame: From baseline to 24 hours after administration ( decoction, oil or vaporized cannabis )

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  12. Area under the concentration-time curve (AUC 0-24 h) of CBD in serum concentrations

    Time frame: From baseline to 24 hours after administration ( decoction, oil or vaporized cannabis )

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

  13. Area under the concentration-time curve (AUC 0-24 h) of CBDA in serum concentrations

    Time frame: From baseline to 24 hours after administration ( decoction, oil or vaporized cannabis )

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours.

Secondary outcomes

  1. Maximum oral fluid concentration (Cmax) of THC

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of maximum concentration (ng/mL) oral fluid samples collected with a Salivette device at the same time points as serum. Ora liquid is collected 15 min before administration (time zero), at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after the oral formulation of cannabis (decoction or oil) and in the case of vaporized cannabis at 15 minutes before zero time (administration), at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours

  2. Maximum oral fluid concentration (Cmax) of THCA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of maximum concentration (ng/mL) oral fluid samples collected with a Salivette device at the same time points as serum. Ora liquid is collected 15 min before administration (time zero), at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after the oral formulation of cannabis (decoction or oil) and in the case of vaporized cannabis at 15 minutes before zero time (administration), at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours

  3. Maximum oral fluid concentration (Cmax) of CBD

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of maximum concentration (ng/mL) oral fluid samples collected with a Salivette device at the same time points as serum. Ora liquid is collected 15 min before administration (time zero), at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after the oral formulation of cannabis (decoction or oil) and in the case of vaporized cannabis at 15 minutes before zero time (administration), at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours

  4. Maximum oral fluid concentration (Cmax) of CBDA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of maximum concentration (ng/mL) oral fluid samples collected with a Salivette device at the same time points as serum. Ora liquid is collected 15 min before administration (time zero), at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after the oral formulation of cannabis (decoction or oil) and in the case of vaporized cannabis at 15 minutes before zero time (administration), at 10, 20, 40, 1, 1.5,2,3,4,6,8 and 24 hours

  5. Time to reach maximum oral fluid concentration (Tmax) of THC

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations

  6. Time to reach maximum oral fluid concentration (Tmax) of THCA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations

  7. Time to reach maximum oral fluid concentration (Tmax) of CBD

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations

  8. Time to reach maximum oral fluid concentration (Tmax) of CBDA

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Time to reach maximun concentration after decoction, oil or vaporized cannabis formulations

  9. Area under the concentration-time curve (AUC 0-24h) of THC oral fluid concentrations

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 hours

  10. Area under the concentration-time curve (AUC 0-24h) of THCA oral fluid concentrations

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 hours

  11. Area under the concentration-time curve (AUC 0-24h) of CBD oral fluid concentrations

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 hours

  12. Area under the concentration-time curve (AUC 0-24h) of CBDA oral fluid concentrations

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Calculation of AUC with samples collected from 15 min prior to administration (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after oral cannabis formulation ( decoction or oil). In the case of vaporized cannabis, serum samples are collected 15 minutes before, at time zero (administration), and at 10, 20, 40, 1, 1.5,2,3,4,6,8 hours

  13. Total amount cannabis metabolites (THC-carboxy and THC-glucoronides, excreted in 24 h urine samples.

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Urine was collected 15 minutes before administration (time zero) and then between 0-2 h, 2-4 h, 6 h-8 h, 8-10 h, and 10-24 h after administration of oral and vaporized formulations.

  14. Total concentration of THC present in sweat after oral and vaporized cannabis administration.

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Concentration in ng/patch. Samples were collected with dermal patches (5 x 5 cm areas) applied to the back and removed at different intervals such as: 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h and 12-24 h

  15. Total concentration of CBD present in sweat after oral and vaporized cannabis administration.

    Time frame: From baseline to 24 hours after decoction, oil or vaporized cannabis administration

    Concentration in ng/patch. Samples were collected with dermal patches (5 x 5 cm areas) applied to the back and removed at different intervals such as: 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h and 12-24 h

  16. Change in blood pressure: Emax (peak/maximum effects) in blood pressure

    Time frame: Differences from baseline to 24 hours

    Non-invasive systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) were repeatedly recorded at baseline (45 and 15 min) prior to decoction or oil administration, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h after administration. In case o vaporized cannabis were recorded at baseline (45 and 15 min) before and 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after administration.

    Blood pressure measured in mmHg.

    .

  17. Change in Heart rate: Emax (peak/maximum effects) in Heart rate

    Time frame: Differences from baseline to 24 hours

    Heart rate were repeatedly recorded at baseline (45 and 15 min) prior to decoction or oil administration, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h after administration. In case of vaporized cannabis were recorded at baseline (45 and 15 min) before and 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after administration .

    Heart rate measured in beats per minute (bpm).

  18. Change in oral temperature: Emax (peak/maximum effects) in oral temperature

    Time frame: Differences from baseline to 24 hours

    Oral temperature were repeatedly recorded at baseline (45 and 15 min) prior to decoction or oil administration, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h after administration. In case o vaporized cannabis were recorded at baseline (45 and 15 min) before and 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after administration .

    Oral temperature measured in Celsius degrees (ºC).

  19. Change in Intensity of effects: Emax (peak/maximum effects) in Intensity of effects

    Time frame: Differences from baseline to 24 hours

    Intensity of effects will be measured using a visual analog scale (0-100 mm) at baseline and 0.30, 1, 1.30, 2, 3, 4, 6,8, 10 and 24 h after oral cannabis administration, and at baseline ,10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after vaporized cannabis administration.

    Higher mm means more intensity of effects.

  20. Change in High feeling: Emax (peak/maximum effects) in High feeling

    Time frame: Differences from baseline to 24 hours

    High will be measured using a visual analog scale 0-100 mm) at baseline and 0.30, 1, 1.30, 2, 3, 4, 6,8, 10 and 24 h after oral cannabis administration , and at baseline ,10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after vaporized cannabis administration.

    Higher mm means more high feeling.

  21. Change in Hunger: Emax (peak/maximum effects) in Hunger

    Time frame: Differences from baseline to 24 hours

    Hunger will be measured using a visual analog scale (0-100 mm) at baseline and 0.30, 1, 1.30, 2, 3, 4, 6,8, 10 and 24 h after oral cannabis administration , and at baseline ,10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after vaporized cannabis administration.

    Higher mm means more hunger.

  22. Change in Drowsines: Emax (peak/maximum effects) in Drowsiness

    Time frame: Differences from baseline to 24 hours

    Drowsiness will be measured using a visual analog scale (0-100 mm) at baseline and 0.30, 1, 1.30, 2, 3, 4, 6,8, 10 and 24 h after oral cannabis administration , and at baseline ,10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after vaporized cannabis administration.

    Higher mm means more drowsiness.

  23. Change in global drug effects: Emax (peak/maximum effects) in global drug effects

    Time frame: Differences from baseline to 24 hours

    Global drug effects will be measured using the short form (49 items) of the Addiction Research Center Inventory (ARCI) . This is a true/false response questionnaire with 49 items. The global results include five subscales (sedation, euphoria, dysphoria, intellectual efficiency and amphetamine-like effects.

    It is administered at baseline and 0.30, 1, 1.30, 2, 3, 4, 6,8, 10 and 24 h after oral cannabis administration , and at baseline, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8, and 24 h after vaporized cannabis administration.

    Scores range usually from a total of 12 to 57 points. More points mean more effects.

Sponsors and collaborators

Lead sponsor

Germans Trias i Pujol Hospital

Other

Collaborators

  • Fundació Institut Germans Trias i Pujol
  • Istituto Superiore di Sanità

Registry information

Official study title

Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation in Healthy Adult Recreational Cannabis Users

Acronym: CANNMED

Important dates

Study start
2018
Primary completion
2019
Study completion
2021
First posted
Apr 12, 2021
Registry last updated
Apr 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.